(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 6.82% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Abbvie's revenue in 2025 is $58,328,000,000.On average, 9 Wall Street analysts forecast ABBV's revenue for 2025 to be $107,117,566,795,733, with the lowest ABBV revenue forecast at $106,828,971,240,174, and the highest ABBV revenue forecast at $107,874,989,246,057. On average, 9 Wall Street analysts forecast ABBV's revenue for 2026 to be $116,998,372,277,442, with the lowest ABBV revenue forecast at $114,679,662,110,001, and the highest ABBV revenue forecast at $120,148,408,859,721.
In 2027, ABBV is forecast to generate $125,309,755,041,278 in revenue, with the lowest revenue forecast at $121,599,942,079,138 and the highest revenue forecast at $130,025,274,916,525.